

EMA/480694/2024

European Medicines Agency decision P/0382/2024

of 31 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (Ebglyss), (EMEA-002536-PIP01-18-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0382/2024

of 31 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (Ebglyss), (EMA-002536-PIP01-18-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0151/2020 issued on 17 April 2020, the decision P/0286/2021 issued on 11 August 2021 and the decision P/0134/2023 issued on 13 April 2023,

Having regard to the application submitted by Eli Lilly and Company Limited on 31 May 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 September 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lebrikizumab (Ebglyss), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU - Bracknell, United Kingdom.

EMA/PDCO/276109/2024
Amsterdam, 6 September 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002536-PIP01-18-M04

Scope of the application

Active substance(s):

Lebrikizumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of atopic dermatitis

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted to the European Medicines Agency on 31 May 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0151/2020 issued on 17 April 2020, the decision P/0286/2021 issued on 11 August 2021 and the decision P/0134/2023 issued on 13 April 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 8 July 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of atopic dermatitis

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of atopic dermatitis

2.1.1. Indication(s) targeted by the PIP

Treatment of moderate to severe atopic dermatitis (AD) inadequately controlled by prescription topical medications

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lebrikizumab in adolescent patients from 12 years to less than 18 years weighing at least 40 kg (and adults) with moderate-to-severe atopic dermatitis (AD). (DRM06-AD04) Study 2 Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lebrikizumab in adolescent patients from 12 years to less than 18 years weighing at least

	40 kg (and adults) with moderate-to-severe AD. (DRM06-AD05) Study 3 Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in adolescent patients from 12 years to less than 18 years weighing at least 40 kg (and adults) with moderate-to-severe atopic dermatitis (AD). (DRM06-AD06) Study 4 Randomized, double-blind, placebo controlled study to evaluate PK, efficacy and safety of lebrikizumab in patients from 6 months to less than 12 years of age and patients from 12 years to less than 18 years of age who weigh less than 40 kg with moderate to severe atopic dermatitis. (DRM06-AD13) Study 5 Study deleted as part of procedure EMEA-002536-PIP01-18-M01 Study 6 Open-label, single-arm study to assess the safety and efficacy of lebrikizumab in adolescent patients from 12 years to less than 18 years with moderate-to-severe atopic dermatitis. (DRM06-AD17)
Extrapolation, modelling and simulation studies	Study 7 Dose finding population PK model to estimate doses in patients from 6 years to less than 18 years of age (DRM06-Model study 1) Study 8 Dose finding population PK model to estimate doses in patients from 6 months to less than 6 years of age (DRM06-Model study 2)
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of atopic dermatitis

Authorised indication(s):

- Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
 - Invented name(s): Ebglyss
 - Authorised pharmaceutical form(s): solution for injection in pre-filled syringe
 - Authorised route(s) of administration: Subcutaneous use
 - Authorised via centralised procedure